NEUROBO PHARMACEUTICALS INC (NRBO)
US64132R2067 - Common Stock
NRBO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 602 industry peers in the Biotechnology industry. NRBO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NRBO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NRBO had negative earnings in the past year.
NRBO had a negative operating cash flow in the past year.
NRBO had negative earnings in each of the past 5 years.
NRBO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NRBO has a Return On Assets (-44.76%) which is in line with its industry peers.
With a decent Return On Equity value of -54.90%, NRBO is doing good in the industry, outperforming 62.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.76% | ||
| ROE | -54.9% | ||
| ROIC | N/A |
ROA(3y)-134.39%
ROA(5y)-134.1%
ROE(3y)-193.7%
ROE(5y)-211.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NRBO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NRBO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NRBO has been increased compared to 5 years ago.
There is no outstanding debt for NRBO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -4.00, we must say that NRBO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.00, NRBO is in line with its industry, outperforming 40.13% of the companies in the same industry.
There is no outstanding debt for NRBO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 5.54 indicates that NRBO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.54, NRBO is in line with its industry, outperforming 54.68% of the companies in the same industry.
NRBO has a Quick Ratio of 5.54. This indicates that NRBO is financially healthy and has no problem in meeting its short term obligations.
NRBO has a Quick ratio of 5.54. This is comparable to the rest of the industry: NRBO outperforms 55.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.54 | ||
| Quick Ratio | 5.54 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 94.76% over the past year.
EPS 1Y (TTM)94.76%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q97.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 25.54% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.34%
EPS Next 2Y40.44%
EPS Next 3Y25.54%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NRBO. In the last year negative earnings were reported.
Also next year NRBO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NRBO's earnings are expected to grow with 25.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.44%
EPS Next 3Y25.54%
5. Dividend
5.1 Amount
No dividends for NRBO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROBO PHARMACEUTICALS INC
NASDAQ:NRBO (11/28/2023, 7:19:44 PM)
After market: 0.425 -0.01 (-1.16%)0.43
+0.01 (+1.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)03-28 2024-03-28/amc
Inst Owners1.06%
Inst Owner Change354.03%
Ins Owners5.55%
Ins Owner Change54.49%
Market Cap16.52M
Analysts85.71
Price Target6.12 (1323.26%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.99%
Min EPS beat(2)17.54%
Max EPS beat(2)84.44%
EPS beat(4)3
Avg EPS beat(4)34.59%
Min EPS beat(4)-48.69%
Max EPS beat(4)85.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.94%
EPS NY rev (1m)0%
EPS NY rev (3m)56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.77 | ||
| P/tB | 0.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.03
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.76% | ||
| ROE | -54.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-134.39%
ROA(5y)-134.1%
ROE(3y)-193.7%
ROE(5y)-211.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.54 | ||
| Quick Ratio | 5.54 | ||
| Altman-Z | -4 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)0%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)94.76%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q97.43%
EPS Next Y97.34%
EPS Next 2Y40.44%
EPS Next 3Y25.54%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.83%
OCF growth 3YN/A
OCF growth 5YN/A